145 related articles for article (PubMed ID: 11205646)
1. Autoantibody profile in progressive systemic sclerosis as markers for esophageal involvement.
Gonzalez R; Storr M; Bloching H; Seige M; Ott R; Allescher HD
J Clin Gastroenterol; 2001 Feb; 32(2):123-7. PubMed ID: 11205646
[TBL] [Abstract][Full Text] [Related]
2. Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study.
Roman S; Hot A; Fabien N; Cordier JF; Miossec P; Ninet J; Mion F;
Dis Esophagus; 2011 Jul; 24(5):299-304. PubMed ID: 21166734
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody profile in systemic sclerosis as a marker for esophageal and other organ involvement in Turkish populations.
Savas N; Dagli U; Ertugrul E; Kuran S; Sahin B
Dig Dis Sci; 2007 Nov; 52(11):3081-6. PubMed ID: 17393310
[TBL] [Abstract][Full Text] [Related]
4. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
5. Clinical correlation of anticentromere antibodies.
Zuber M; Gotzen R; Filler I
Clin Rheumatol; 1994 Sep; 13(3):427-32. PubMed ID: 7835004
[TBL] [Abstract][Full Text] [Related]
6. Esophageal function in systemic sclerosis: a prospective evaluation of motility and acid reflux in 36 patients.
Yarze JC; Varga J; Stampfl D; Castell DO; Jimenez SA
Am J Gastroenterol; 1993 Jun; 88(6):870-6. PubMed ID: 8503383
[TBL] [Abstract][Full Text] [Related]
7. The concurrence of rheumatoid arthritis and limited systemic sclerosis: clinical and serologic characteristics of an overlap syndrome.
Zimmermann C; Steiner G; Skriner K; Hassfeld W; Petera P; Smolen JS
Arthritis Rheum; 1998 Nov; 41(11):1938-45. PubMed ID: 9811047
[TBL] [Abstract][Full Text] [Related]
8. Anticentromere antibody--clinical associations. A study of 44 patients.
Caramaschi P; Biasi D; Manzo T; Carletto A; Poli F; Bambara LM
Rheumatol Int; 1995; 14(6):253-5. PubMed ID: 7597381
[TBL] [Abstract][Full Text] [Related]
9. [Changes in esophageal peristalsis in diverse clinical forms and antibody specificity in scleroderma: a scintigraphic study in 100 cases].
Cozzi F; Zucchetta P; Durigon N; Marzola MC; Bullo A; Favaro M; Bui F; Todesco S
Reumatismo; 2003; 55(2):86-92. PubMed ID: 12874641
[TBL] [Abstract][Full Text] [Related]
10. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.
Mitri GM; Lucas M; Fertig N; Steen VD; Medsger TA
Arthritis Rheum; 2003 Jan; 48(1):203-9. PubMed ID: 12528120
[TBL] [Abstract][Full Text] [Related]
11. Anti-centromere antibodies in patients with systemic lupus erythematosus.
Respaldiza N; Wichmann I; Ocaña C; Garcia-Hernandez FJ; Castillo MJ; Magariño MI; Magariño R; Torres A; Sanchez-Roman J; Nuñez-Roldan A
Scand J Rheumatol; 2006; 35(4):290-4. PubMed ID: 16882593
[TBL] [Abstract][Full Text] [Related]
12. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
[TBL] [Abstract][Full Text] [Related]
13. [Is there a place of multiantigenes immunodot determination in systemic sclerosis patients without anti-centromeres or anti-Scl70 antibodies?].
Sautereau N; Gabsi A; Daumas A; Bardin N; Granel B
Presse Med; 2015 May; 44(5):547-9. PubMed ID: 25813097
[No Abstract] [Full Text] [Related]
14. [Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases)].
Admou B; Arji N; Seghrouchni F; Missoum H; El Fenniri L; Amghar S; El Aouad R
Ann Biol Clin (Paris); 2007; 65(3):291-7. PubMed ID: 17502303
[TBL] [Abstract][Full Text] [Related]
15. Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants.
McCarty GA; Rice JR; Bembe ML; Barada FA
Arthritis Rheum; 1983 Jan; 26(1):1-7. PubMed ID: 6337593
[TBL] [Abstract][Full Text] [Related]
16. [Nuclear antibodies as serologic markers in progressive systemic scleroderma].
Lakomek HJ; Guldner HH; Bautz FA; Goerz G; Kind P; Mensing H; Krüskemper HL
Hautarzt; 1987 Feb; 38(2):63-9. PubMed ID: 3106261
[TBL] [Abstract][Full Text] [Related]
17. Incidence and clinical correlation of anticentromere antibody in Thai patients.
Pakunpanya K; Verasertniyom O; Vanichapuntu M; Pisitkun P; Totemchokchyakarn K; Nantiruj K; Janwityanujit S
Clin Rheumatol; 2006 May; 25(3):325-8. PubMed ID: 16220222
[TBL] [Abstract][Full Text] [Related]
18. [Functional study of the esophagus in progressive systemic sclerosis: utility of the manometry].
Foggi E; Spaggiari L; Carbognani P; Rusca M; Soliani P; Dell'Abate P
Acta Biomed Ateneo Parmense; 1991; 62(5-6):155-60. PubMed ID: 1844190
[TBL] [Abstract][Full Text] [Related]
19. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis.
Chorzelski TP; Jablonska S; Beutner EH; Blaszczyk M; Jarzabek-Chorzelska M; Kencka D; Krasny S; Kumar V; Tchórzewska A
Br J Dermatol; 1985 Oct; 113(4):381-9. PubMed ID: 3877519
[TBL] [Abstract][Full Text] [Related]
20. Scl 70 antibody--a specific marker of systemic sclerosis.
Jarzabek-Chorzelska M; Blaszczyk M; Jablonska S; Chorzelski T; Kumar V; Beutner EH
Br J Dermatol; 1986 Oct; 115(4):393-401. PubMed ID: 3535866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
